



## Press Release

### **CILIAN granted new US patent for its expression system**

**Münster, Germany, June 2012:**

CILIAN AG was granted a new patent in the US for its proprietary expression technology brand named CIPEX System (Ciliates Performance Expression System). This new patent makes the use of antibiotics in the production process of biopharmaceuticals obsolete when manufactured with CIPEX.

CILIAN AG already possesses a large patent estate for its technology platform as well as its own drug product. A number of additional patents are currently pending. The latest granted patent is US 8,114,650.

#### **About Cilian AG**

Founded in 2001 by Dr. Marcus Hartmann, CILIAN AG is an emerging German biotechnology company developing and marketing a novel expression system. The Company uses a species of Ciliates, a eukaryotic single-cell organism, for the production of therapeutic proteins.

#### **About CIPEX System**

Cilian developed its innovative proprietary technology brand named CIPEX System for the development and production of biopharmaceuticals. This system is more efficient, safer and more cost effective than traditional systems particularly for production of vaccines, antitumor antibodies and therapeutic enzymes.

For further information, visit [www.cilian.com](http://www.cilian.com) or contact:

#### **Cilian AG:**

Marcus Hartmann, Ph.D. (CSO)

tel. +49 251 6 20 310

hartmann@cilian.de